HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Wednesday, 16 May 2018

April’s CEAs.....

Our quick search for CEA’s published in April uncovered 52 articles.   In the right-hand column of this blog is a CEA Archive, which includes our CEA search results by month.  Below are those in our areas of interest.
  • Barnett AH, Arnoldini S, Hunt B, Subramanian G, Hoxer CS. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis. Diabetes, obesity & metabolism. 2018.
  • Dawkins BR, Mirelman AJ, Asaria M, Johansson KA, Cookson RA. Distributional cost-effectiveness analysis in low- and middle-income countries: illustrative example of rotavirus vaccination in Ethiopia. Health policy and planning. 2018;33(3):456-63.
  • Henry N, Jovanovic J, Schlueter M, Kritikou P, Wilson K, Myren KJ. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden. Journal of medical economics. 2018;21(4):318-25.
  • Leurent B, Gomes M, Faria R, Morris S, Grieve R, Carpenter JR. Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial. PharmacoEconomics. 2018.
  • Vilsboll AW, Mouritsen JM, Jensen LP, Bodker N, Holst AW, Pennisi CP, et al. Cell-based therapy for the treatment of female stress urinary incontinence: an early cost-effectiveness analysis. Regenerative medicine. 2018;13(3):321-30.

Posted by at